FORXIGA® (dapagliflozin) is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1
FORXIGA® (dapagliflozin) therapeutic indications and dosing
FORXIGA® (dapagliflozin) is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as:1
When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.1
Add-on combination therapy
In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.1
The recommended dose is FORXIGA® (dapagliflozin) 10 mg once daily for monotherapy and add-on combination therapy with other glucose-lowering medicinal products including insulin.1
FORXIGA® (dapagliflozin) is not recommended for use in patients with an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m.1 The use of FORXIGA® (dapagliflozin) with pioglitazone is not recommended.1 In patients with severe hepatic impairment a starting dose of 5 mg is recommended. If well-tolerated, the dose may be increased to 10 mg.1 When dapagliflozin is used in combination with insulin or insulin secretagogue, such as a sulphonylurea, a lower dose of insulin or insulin secretagogue may be considered to reduce the risk of hypoglycaemia.